Conference Coverage

What Distinguishes MS From Its Mimics?


 

Suggested Reading

Costello DJ, Eichler AF, Eichler FS. Leukodystrophies: classification, diagnosis, and treatment. Neurologist. 2009;15(6):319-328.

Kleinfeld K, Mobley B, Hedera P, et al. Adult-onset leukoencephalopathy with neuroaxonal spheroids and pigmented glia: report of five cases and a new mutation. J Neurol. 2013;260(2):558-571.

Pawate S, Agarwal A, Moses H, Sriram S. The spectrum of Susac’s syndrome. Neurol Sci. 2009;30(1):59-64.

Pages

Recommended Reading

Durable Efficacy of Cladribine Tablets After Conversion to Clinically Definite MS
ICYMI Multiple Sclerosis
Retinal Measurements Predict 10-Year Disability in MS
ICYMI Multiple Sclerosis
Telerehabilitation May Be As Effective As In-Person Rehabilitation in MS
ICYMI Multiple Sclerosis
Can Neurologists Predict Long-Term Disability Trajectories in Primary Progressive MS?
ICYMI Multiple Sclerosis
Does the EDSS Capture Cognitive Difficulties in Patients With MS?
ICYMI Multiple Sclerosis
Durable Efficacy of Alemtuzumab: Five-Year Follow-Up of the CARE-MS Studies
ICYMI Multiple Sclerosis
Arbaclofen Extended-Release Tablets Are Effective for MS Spasticity
ICYMI Multiple Sclerosis
Ocrelizumab Increases Likelihood of No Evidence of Disease Progression
ICYMI Multiple Sclerosis
Siponimod curbs disability in secondary progressive multiple sclerosis
ICYMI Multiple Sclerosis
Alemtuzumab, natalizumab found equally effective for relapsing-remitting MS
ICYMI Multiple Sclerosis